Smith Andrew M, Bernstein David I
Division of Immunology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio 45267-0563, USA.
J Allergy Clin Immunol. 2009 Mar;123(3):551-7. doi: 10.1016/j.jaci.2008.12.1129.
The physician managing work-related asthma (WRA) assumes many roles. The first is to confirm an accurate diagnosis, recognizing that WRA has multiple phenotypes, including sensitizer-induced occupational asthma (OA) caused by high-molecular-weight (HMW) proteins or low-molecular-weight (LMW) chemicals; irritant-induced asthma; and work-exacerbated asthma. Pharmacotherapy for WRA is identical to nonwork-related asthma and should be guided by current asthma guidelines emphasizing control of both asthma impairment and risk domains. It is well established that the majority of workers diagnosed with OA caused by sensitizers experience persistent asthma after leaving the workplace. However, the long-term risk of persistent unremitting asthma can be prevented in a minority of cases, particularly with OA caused by LMW sensitizers, by establishing an early diagnosis of OA and reducing or eliminating exposure. The physician consultant may advise employers on workplace interventions needed to minimize effectively an affected employee's exposure to a causative agent or condition, and what measures are required to prevent new cases of WRA (ie, primary prevention). Although allergen immunotherapy has a putative role in treating and preventing WRA caused by HMW sensitizers, further study is needed.
管理职业性哮喘(WRA)的医生承担着多种角色。首先是要做出准确诊断,认识到WRA有多种表型,包括由高分子量(HMW)蛋白质或低分子量(LMW)化学物质引起的致敏剂诱发的职业性哮喘(OA);刺激性哮喘;以及工作加重性哮喘。WRA的药物治疗与非职业性哮喘相同,应遵循当前强调控制哮喘损害和风险领域的哮喘指南。众所周知,大多数被诊断为由致敏剂引起的OA的工人在离开工作场所后会经历持续性哮喘。然而,在少数情况下,特别是对于由LMW致敏剂引起的OA,通过早期诊断OA并减少或消除接触,可以预防持续性哮喘的长期风险。医生顾问可以就有效减少受影响员工接触致病因子或条件所需的工作场所干预措施,以及预防WRA新病例(即一级预防)所需的措施向雇主提供建议。尽管变应原免疫疗法在治疗和预防由HMW致敏剂引起的WRA方面有假定作用,但仍需要进一步研究。